![Mark O’Mahony](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark O’Mahony
Keine laufenden Positionen mehr
Vermögen: 31 075 $ am 31.05.2026
Profil
Mark O’Mahony formerly worked at Millennium Pharmaceuticals, Inc., as Principal in 2000, LeukoSite, Inc., as Principal in 2000, Tolerx, Inc., as VP-Process Development & Manufacturing from 2000 to 2011, DecImmune Therapeutics, Inc., as Vice President-Manufacturing & Quality, Serono Corp., as Principal, and Leap Therapeutics, Inc., as Vice President-Manufacturing from 2011 to 2020.
Mr. O’Mahony received his Masters Business Admin degree from Boston University and undergraduate degree from University College Dublin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.03.2025 | 27.500 ( 0,03 % ) | 31 075 $ | 31.05.2026 |
Ehemalige bekannte Positionen von Mark O’Mahony
| Unternehmen | Position | Ende |
|---|---|---|
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Corporate Officer/Principal | 19.12.2011 |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Corporate Officer/Principal | 01.01.2000 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 01.01.2000 |
| CYPHERPUNK TECHNOLOGIES INC. | Corporate Officer/Principal | - |
DecImmune Therapeutics, Inc.
 DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Corporate Officer/Principal | - |
Ausbildung von Mark O’Mahony
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
75
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College Dublin
 University College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Serono Corp. | |
Leap Therapeutics, Inc.
 Leap Therapeutics, Inc. BiotechnologyHealth Technology Engages in clinical stage immuno-oncology | Health Technology |
Wählen Sie MarketScreener 
